Precision Medicine

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

OncLive® unveils its 2026 class of inductees, 14 visionaries whose groundbreaking work is transforming the future of oncology and bringing hope to millions.

An innovative RNA-editing therapy for hepatocellular carcinoma has received a major FDA designation, potentially accelerating its path to patients.

As Talphera preps its Q1 update, all eyes are on its breakthrough drug Niyad® and the mounting costs of bringing a potential game-changer to market.

A new AI-powered technology can spot deadly high potassium levels using a simple smartwatch ECG, a breakthrough that could transform remote patient care.

UWorld and the Goldwater Foundation award 93 top students, fueling the pipeline of medical researchers poised to tackle society's biggest health challenges.

A new drug shows major promise for a painful heart condition, with pivotal study results accepted by a top journal and a final-stage trial speeding ahead.

A landmark clinical trial suggests a different form of folate may be better for pregnancy, reducing a controversial byproduct without sacrificing key benefits.

A free virtual summit unites 20+ experts to share science-based strategies, blending traditional and lifestyle medicine to fight preventable blindness.

The diagnostics firm's stellar quarter is fueled by surging test volumes and a new non-invasive prenatal test poised to disrupt high-risk screening.

LifeMD posts record subscriber growth in Q1 driven by GLP-1 and women's health, but a planned loss from heavy marketing spend raises key questions.

Diathrive Health and AliveCor's KardiaComplete partner to offer an integrated solution for diabetes and heart disease, combating fragmented care and rising costs.

A new obesity drug shows 19.3% weight loss with remarkably few side effects, while also improving blood pressure, cholesterol, and even bone density.

With a key FDA decision looming, Cristcot hires Rayna Herman to lead the commercial strategy for its first-in-class ulcerative colitis therapy, ngHCA.

As EyePoint's losses widen to fund its lead drug, DURAVYU, the company is on the cusp of pivotal trial results that could redefine retinal disease treatment.

Seattle-based Alpenglow Biosciences launches Summit AI, a platform moving tissue analysis beyond flat 2D slides into comprehensive 3D for drug development.

The Sugar Ray Leonard Foundation's 15th annual charity boxing night will honor Dr. Jennifer Raymond for her groundbreaking work in pediatric diabetes care.

Medical tech giant Convatec unveils a new arsenal of advanced wound care solutions, using nitric oxide and placental tech to combat hard-to-heal injuries.

A new report reveals a dramatic shift in Alzheimer's drug development, with 75% of trials now targeting pathways beyond amyloid for a new age of treatment.

A new blood test could tell you if GLP-1 drugs will work for you before you start, a major leap for precision medicine in the booming obesity market.